Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice

Wenwu Zhang, Patricia G. Yancey, Yan Ru Su, Vladimir R. Babaev, Yuomin Zhang, Sergio Fazio, MacRae F. Linton

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Background - Scavenger receptor class B type I (SR-BI) is expressed in macrophages, where it has been proposed to facilitate cholesterol efflux. However, direct evidence that the expression of macrophage SR-BI is protective against atherosclerosis is lacking. In this study, we examined the in vivo role of macrophage SR-BI in atherosclerotic lesion development in the apolipoprotein (apo) E-deficient mouse model. Methods and Results - ApoE-deficient mice with (n=16) or without (n=15) expression of macrophage SR-BI were created by transplanting lethally irradiated apoE-deficient mice with bone marrow cells collected from SR-BI-/- apoE-/- mice or SR-BI +/+ apoE-/- mice. The recipient mice were fed a chow diet for 12 weeks after transplantation for analysis of atherosclerosis. Quantification of macrophage SR-BI mRNA by real-time reverse transcription-polymerase chain reaction indicated successful engraftment of donor bone marrow and inactivation of macrophage SR-BI in recipient mice reconstituted with SR-BI-/- apoE-/- bone marrow. There were no significant differences in plasma lipid levels, lipoprotein distributions, and HDL subpopulations between the 2 groups. Analysis of the proximal aorta demonstrated an 86% increase in mean atherosclerotic lesion area in SR-BI-/- apoE-/- → apoE-/- mice compared with SR-BI+/+ apoE-/- → apoE-/- mice (109.50±18.08 versus 58.75±9.58×103 μm2; mean±SEM, P=0.017). No difference in cholesterol efflux from SR-BI+/+ apoE-/- or SR-BI-/- apoE-/- macrophages to HDL or apoA-I discs was detected. Conclusions - Expression of macrophage SR-BI protects mice against atherosclerotic lesion development in apoE-deficient mice in vivo without influencing plasma lipids, HDL subpopulations, or cholesterol efflux. Thus, macrophage SR-BI plays an antiatherogenic role in vivo, providing a new therapeutic target for the design of strategies to prevent and treat atherosclerosis.

Original languageEnglish (US)
Pages (from-to)2258-2263
Number of pages6
JournalCirculation
Volume108
Issue number18
DOIs
StatePublished - Nov 4 2003
Externally publishedYes

Fingerprint

CD36 Antigens
Scavenger Receptors
Apolipoproteins E
Low Density Lipoprotein Receptor-Related Protein-1
Atherosclerosis
Cholesterol
Bone Marrow
Macrophages
Lipids
Apolipoprotein A-I

Keywords

  • Atherosclerosis
  • Cholesterol
  • Macrophages
  • Receptors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice. / Zhang, Wenwu; Yancey, Patricia G.; Su, Yan Ru; Babaev, Vladimir R.; Zhang, Yuomin; Fazio, Sergio; Linton, MacRae F.

In: Circulation, Vol. 108, No. 18, 04.11.2003, p. 2258-2263.

Research output: Contribution to journalArticle

Zhang, Wenwu ; Yancey, Patricia G. ; Su, Yan Ru ; Babaev, Vladimir R. ; Zhang, Yuomin ; Fazio, Sergio ; Linton, MacRae F. / Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice. In: Circulation. 2003 ; Vol. 108, No. 18. pp. 2258-2263.
@article{337064e739884575b5cc0ab5b8e07b64,
title = "Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice",
abstract = "Background - Scavenger receptor class B type I (SR-BI) is expressed in macrophages, where it has been proposed to facilitate cholesterol efflux. However, direct evidence that the expression of macrophage SR-BI is protective against atherosclerosis is lacking. In this study, we examined the in vivo role of macrophage SR-BI in atherosclerotic lesion development in the apolipoprotein (apo) E-deficient mouse model. Methods and Results - ApoE-deficient mice with (n=16) or without (n=15) expression of macrophage SR-BI were created by transplanting lethally irradiated apoE-deficient mice with bone marrow cells collected from SR-BI-/- apoE-/- mice or SR-BI +/+ apoE-/- mice. The recipient mice were fed a chow diet for 12 weeks after transplantation for analysis of atherosclerosis. Quantification of macrophage SR-BI mRNA by real-time reverse transcription-polymerase chain reaction indicated successful engraftment of donor bone marrow and inactivation of macrophage SR-BI in recipient mice reconstituted with SR-BI-/- apoE-/- bone marrow. There were no significant differences in plasma lipid levels, lipoprotein distributions, and HDL subpopulations between the 2 groups. Analysis of the proximal aorta demonstrated an 86{\%} increase in mean atherosclerotic lesion area in SR-BI-/- apoE-/- → apoE-/- mice compared with SR-BI+/+ apoE-/- → apoE-/- mice (109.50±18.08 versus 58.75±9.58×103 μm2; mean±SEM, P=0.017). No difference in cholesterol efflux from SR-BI+/+ apoE-/- or SR-BI-/- apoE-/- macrophages to HDL or apoA-I discs was detected. Conclusions - Expression of macrophage SR-BI protects mice against atherosclerotic lesion development in apoE-deficient mice in vivo without influencing plasma lipids, HDL subpopulations, or cholesterol efflux. Thus, macrophage SR-BI plays an antiatherogenic role in vivo, providing a new therapeutic target for the design of strategies to prevent and treat atherosclerosis.",
keywords = "Atherosclerosis, Cholesterol, Macrophages, Receptors",
author = "Wenwu Zhang and Yancey, {Patricia G.} and Su, {Yan Ru} and Babaev, {Vladimir R.} and Yuomin Zhang and Sergio Fazio and Linton, {MacRae F.}",
year = "2003",
month = "11",
day = "4",
doi = "10.1161/01.CIR.0000093189.97429.9D",
language = "English (US)",
volume = "108",
pages = "2258--2263",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice

AU - Zhang, Wenwu

AU - Yancey, Patricia G.

AU - Su, Yan Ru

AU - Babaev, Vladimir R.

AU - Zhang, Yuomin

AU - Fazio, Sergio

AU - Linton, MacRae F.

PY - 2003/11/4

Y1 - 2003/11/4

N2 - Background - Scavenger receptor class B type I (SR-BI) is expressed in macrophages, where it has been proposed to facilitate cholesterol efflux. However, direct evidence that the expression of macrophage SR-BI is protective against atherosclerosis is lacking. In this study, we examined the in vivo role of macrophage SR-BI in atherosclerotic lesion development in the apolipoprotein (apo) E-deficient mouse model. Methods and Results - ApoE-deficient mice with (n=16) or without (n=15) expression of macrophage SR-BI were created by transplanting lethally irradiated apoE-deficient mice with bone marrow cells collected from SR-BI-/- apoE-/- mice or SR-BI +/+ apoE-/- mice. The recipient mice were fed a chow diet for 12 weeks after transplantation for analysis of atherosclerosis. Quantification of macrophage SR-BI mRNA by real-time reverse transcription-polymerase chain reaction indicated successful engraftment of donor bone marrow and inactivation of macrophage SR-BI in recipient mice reconstituted with SR-BI-/- apoE-/- bone marrow. There were no significant differences in plasma lipid levels, lipoprotein distributions, and HDL subpopulations between the 2 groups. Analysis of the proximal aorta demonstrated an 86% increase in mean atherosclerotic lesion area in SR-BI-/- apoE-/- → apoE-/- mice compared with SR-BI+/+ apoE-/- → apoE-/- mice (109.50±18.08 versus 58.75±9.58×103 μm2; mean±SEM, P=0.017). No difference in cholesterol efflux from SR-BI+/+ apoE-/- or SR-BI-/- apoE-/- macrophages to HDL or apoA-I discs was detected. Conclusions - Expression of macrophage SR-BI protects mice against atherosclerotic lesion development in apoE-deficient mice in vivo without influencing plasma lipids, HDL subpopulations, or cholesterol efflux. Thus, macrophage SR-BI plays an antiatherogenic role in vivo, providing a new therapeutic target for the design of strategies to prevent and treat atherosclerosis.

AB - Background - Scavenger receptor class B type I (SR-BI) is expressed in macrophages, where it has been proposed to facilitate cholesterol efflux. However, direct evidence that the expression of macrophage SR-BI is protective against atherosclerosis is lacking. In this study, we examined the in vivo role of macrophage SR-BI in atherosclerotic lesion development in the apolipoprotein (apo) E-deficient mouse model. Methods and Results - ApoE-deficient mice with (n=16) or without (n=15) expression of macrophage SR-BI were created by transplanting lethally irradiated apoE-deficient mice with bone marrow cells collected from SR-BI-/- apoE-/- mice or SR-BI +/+ apoE-/- mice. The recipient mice were fed a chow diet for 12 weeks after transplantation for analysis of atherosclerosis. Quantification of macrophage SR-BI mRNA by real-time reverse transcription-polymerase chain reaction indicated successful engraftment of donor bone marrow and inactivation of macrophage SR-BI in recipient mice reconstituted with SR-BI-/- apoE-/- bone marrow. There were no significant differences in plasma lipid levels, lipoprotein distributions, and HDL subpopulations between the 2 groups. Analysis of the proximal aorta demonstrated an 86% increase in mean atherosclerotic lesion area in SR-BI-/- apoE-/- → apoE-/- mice compared with SR-BI+/+ apoE-/- → apoE-/- mice (109.50±18.08 versus 58.75±9.58×103 μm2; mean±SEM, P=0.017). No difference in cholesterol efflux from SR-BI+/+ apoE-/- or SR-BI-/- apoE-/- macrophages to HDL or apoA-I discs was detected. Conclusions - Expression of macrophage SR-BI protects mice against atherosclerotic lesion development in apoE-deficient mice in vivo without influencing plasma lipids, HDL subpopulations, or cholesterol efflux. Thus, macrophage SR-BI plays an antiatherogenic role in vivo, providing a new therapeutic target for the design of strategies to prevent and treat atherosclerosis.

KW - Atherosclerosis

KW - Cholesterol

KW - Macrophages

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=0242266978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242266978&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000093189.97429.9D

DO - 10.1161/01.CIR.0000093189.97429.9D

M3 - Article

C2 - 14581413

AN - SCOPUS:0242266978

VL - 108

SP - 2258

EP - 2263

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 18

ER -